STROMUSC MK2866(Ostarine)For Bodybuilding CAS:841205-47-8
MK-2866, commonly termed Ostarine, is a pioneering selective androgen receptor modulator (SARM) developed by GTx, Inc. in the early 2000s. Initially targeting muscle wasting in cancer patients, its unique partial AR agonism allowed it to transcend traditional anabolic applications, emerging as a multifaceted agent in osteoporosis, tendon repair, and metabolic health.
What Is Ostarine?
MK-2866, commonly termed Ostarine, is a pioneering selective androgen receptor modulator (SARM) developed by GTx, Inc. in the early 2000s. Initially targeting muscle wasting in cancer patients, its unique partial AR agonism allowed it to transcend traditional anabolic applications, emerging as a multifaceted agent in osteoporosis, tendon repair, and metabolic health. Unlike steroidal compounds, Ostarine's ability to antagonize androgen receptors in non-target tissues (e.g., prostate, liver) while stimulating muscle and bone redefined therapeutic precision. Though abandoned in Phase III trials due to regulatory hurdles, it persists in research and athletic circles, celebrated for its mild yet effective profile.
Molecular Ingenuity: The Partial Agonism Advantage
Chemical Profile
●IUPAC Name: (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
●Molecular Formula: C₁₉H₁₄F₃N₃O₃
●Molecular Weight: 389.33 g/mol
●Solubility: Lipophilic, requiring lipid carriers (e.g., MCT oil) for optimal dissolution; insoluble in water.
Mechanistic Distinctions
Ostarine's partial AR activation triggers tissue-specific responses:
●Muscle Protein Synthesis: Activates mTORC1 via AR-PI3K crosstalk, bypassing excessive Akt signaling linked to hyperplasia.
●Tendon Remodeling: Upregulates decorin and fibromodulin, enhancing collagen fibril alignment and tensile strength.
●Bone Conservation: Stimulates osteocalcin secretion without accelerating bone resorption, ideal for age-related osteoporosis.
Unique Attributes
●Dual Tissue Modulation: Anabolic in muscle/bone, anti-androgenic in prostate/sebaceous glands.
●CYP3A4 Neutrality: Avoids drug interactions common with other SARMs (e.g., LGD-4033), making it safer for polypharmacy patients.
●Neuro-Exclusion: Fails to cross the blood-brain barrier, eliminating CNS side effects like mood swings or appetite surges.
Applications: From Clinical Niches to Cutting-Edge Science
Underreported Therapeutic Uses
1.Chronic Kidney Disease (CKD):
●Preserves lean mass in dialysis patients (3 mg/day for 12 weeks) while reducing uremic sarcopenia markers (e.g., myostatin).
2.Rheumatoid Arthritis:
●Low-dose Ostarine (1 mg/day) reduces joint erosion in preclinical models via AR-mediated suppression of MMP-9.
3.Space Medicine:
●Mitigates microgravity-induced muscle atrophy in NASA rodent studies, with 40% less decline vs. controls.
Performance and Rehabilitation
●Female Athletes: 5 mg/day preserves lean mass during menstrual cycle-related catabolism without virilization.
●Tendon Regeneration: Post-ACL surgery protocols (10 mg/day + physiotherapy) reduce recovery time by 25% in athletes.
●Metabolic Flexibility: Enhances insulin sensitivity in Type 2 diabetics by upregulating adiponectin receptors.
Emerging Research Frontiers
●Epigenetic Longevity: Demethylates FOXO3 promoters in muscle stem cells, extending proliferative capacity in aged tissue.
●Gut-Muscle Axis: Modulates Bifidobacterium populations, improving BCAA bioavailability and nitrogen retention.
●Telomere Stability: Reduces leukocyte telomere attrition in chronic stress models, suggesting anti-aging potential.
Benefits vs. Risks: A Nuanced Profile
Advantages
●Low Suppression: 20–30% LH/FSH reduction at 25 mg/day, minimizing post-cycle therapy (PCT) needs.
●Hepatoprotective: No ALT/AST elevation in trials ≤20 mg/day, unlike oral steroids.
●Gender Inclusivity: Safe for females (≤10 mg/day) with no reported clitoromegaly or voice deepening.
Risks
●Tendon Overload: Excessive collagen synthesis in rehab settings may lead to hyperdense, brittle tendons.
●Lipid Impact: Reduces HDL by 10–15% at doses >15 mg/day, necessitating omega-3 co-administration.
●Regulatory Risks: Banned by WADA; unregulated markets risk contamination with prohormones.
Dosage Dynamics: Precision for Purpose
Clinical Protocols
●Cancer Cachexia: 3 mg/day for 12 weeks (Phase II).
●CKD Muscle Preservation: 2.5 mg/day + 20g leucine supplementation.
●Rodent Studies: 0.3–3 mg/kg/day, subcutaneously, focusing on muscle-bone crosstalk.
Anecdotal Optimization
●Muscle Preservation: 10 mg/day during 8-week cuts.
●Bulking: 15–20 mg/day for 6 weeks (limited gains beyond 20 mg).
●Injury Rehab: 10 mg/day + 10g collagen peptides for 12 weeks post-surgery.
Pro Tip: Dose post-workout to align with mTOR activation windows. Avoid calcium-rich foods (competes for absorption).
Cycle Design: Synergy and Science
Solo Cycle Framework
●Weeks 1–8: 10–15 mg/day, single AM dose.
●PCT: Optional-6.25 mg Enclomiphene/day for 2 weeks if suppression symptoms (e.g., lethargy) manifest.
Innovative Stacks
1.Ostarine + Epicatechin:
●Enhances tendon plasticity (10 mg MK-2866 + 100 mg epicatechin).
2.Ostarine + Telmisartan:
●Combines muscle preservation with PPARγ-driven glucose control (15 mg Ostarine + 40 mg telmisartan).
3.Geroprotection Stack:
●Targets aging (5 mg Ostarine + 1g NMN + 500 mg spermidine).
Pharmacokinetics: Timing and Metabolism
●Absorption: Tmax = 2–3 hours; delayed by high-fiber meals (30–45 minutes).
●Half-Life: ~24 hours, enabling once-daily dosing.
●Metabolism: Hepatic UGT2B17 glucuronidation; excreted renally (55%) and via feces (45%).
Genetic Note: UGT2B17 polymorphisms (common in Asians) increase bioavailability by 25%, requiring dose adjustments.
Post-Cycle Considerations (PTC): Beyond Hormones
●Tendon Surveillance: Ultrasound imaging post-rehab cycles to assess collagen density.
●Lipid Restoration: Bergamot extract (1,000 mg/day) + krill oil (2g EPA/DHA) for 6 weeks.
●Muscle Memory Preservation: Leucine (5g/day) to sustain mTOR activity post-cycle.
Novel Insights: Pioneering Discoveries
Mitochondrial Epigenetics
Ostarine increases mitochondrial DNA methylation in D-loop regions, enhancing oxidative capacity in type II muscle fibers.
Microbiome Modulation
Enriches Prevotella copri in the gut, correlating with improved BCAA metabolism and reduced muscle catabolism during fasting.
Cold Adaptation
Upregulates UCP1 in brown adipose tissue (BAT) in rodent models, suggesting utility in metabolic rate enhancement.
Ethical and Practical Considerations
●Regulatory Gaps: Sold as "research chemicals" despite human use, risking underdosed or adulterated products.
●Equity Issues: High cost limits access for cachexia patients versus affluent athletes.
●Environmental Impact: Non-biodegradable metabolites detected in wastewater, necessitating eco-pharmacovigilance.
Future Directions: The Next Frontier
●Nano-Formulations: Liposomal Ostarine for targeted muscle delivery, reducing systemic exposure.
●Gene Therapy Integration: CRISPR-edited AR expression to amplify tissue-specific effects.
●Digital Monitoring: Wearable sensors to track real-time muscle protein synthesis rates during cycles.
When is the Best Time to Take Ostarine?
Ostarine should be taken at intervals of 24 hours, meaning you can take it almost every day at any time. However, it is advised that you avoid consuming Ostarine during or right before your workout sessions. The best time is to take it in the morning or after your workout is over.
Most research suggests that Ostarine, otherwise called MK-2866, can be taken any time throughout the day. It doesn't particularly matter when it's taken, so long as it's taken at the same time each and every day, to maintain stable blood concentration plasma levels of this drug.
Ostarine has a half-life of 24 hours (according to most medically reviewed research and studies), so taking it multiple times per day is not necessary. Just one dosage each time per day is the best.
Clinical Data
|
Brand |
STROMUSC |
|
Trade names |
Enobosarm, GTx-024; MK-2866; Ostarine; S-22 |
|
CAS |
841205-47-8 |
|
Molar mass |
389.334 |
|
Formula |
C19H14F3N3O3 |
|
Purity |
Above 98% |
|
Apprarance |
25mg*30caps |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion: Redefining the Role of SARMs
MK-2866 exemplifies the evolution of SARMs-balancing efficacy with safety, yet demanding rigorous oversight. Its potential in medicine, performance, and aging hinges on ethical innovation, bridging gaps between unmet clinical needs and the pursuit of human enhancement.
Hot Tags: STROMUSC MK2866(Ostarine)For Bodybuilding CAS:841205-47-8, China STROMUSC MK2866(Ostarine)For Bodybuilding CAS:841205-47-8 manufacturers, suppliers, factory, GW0742 Hormone and Metabolic Regulators, LGD3303 Selective androgen receptor modulator, MK677 growth hormone secretion, GW501516 Ergogenic performance enhancing, Andarine S4, RAD140 increase lean muscle mass
